MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

RECAB-ASA; Treatment of Recurrent Abortion With Aspirin

Not Applicable
Completed
Conditions
Abortion, Habitual
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2016-07-06
Last Posted Date
2016-07-06
Lead Sponsor
Göteborg University
Target Recruit Count
400
Registration Number
NCT02823743

Perioperative Bleeding and Aspirin Use in Spine Surgery

Phase 3
Withdrawn
Conditions
Hemorrhage
Thrombosis
Interventions
First Posted Date
2016-06-21
Last Posted Date
2021-10-11
Lead Sponsor
University Hospitals Cleveland Medical Center
Registration Number
NCT02807441
Locations
🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

Low Dose Aspirin in the Prevention of Preeclampsia in China

Phase 3
Completed
Conditions
Preeclampsia
Interventions
Other: Blank
Drug: Aspirin
First Posted Date
2016-06-13
Last Posted Date
2019-05-01
Lead Sponsor
Peking University First Hospital
Target Recruit Count
1000
Registration Number
NCT02797249
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Phase 4
Terminated
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2016-06-01
Last Posted Date
2016-06-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
190
Registration Number
NCT02786979
Locations
🇨🇳

Site CN00006, Tianjin, Tianjin, China

🇨🇳

Site CN00001, Beijing, Beijing, China

🇨🇳

Site CN00003, Shanghai, Shanghai, China

and more 3 locations

Clopidogrel for Acute Ischaemia of Recent Onset

Phase 4
Completed
Conditions
Ischemic Cerebrovascular Accident
Interventions
First Posted Date
2016-05-18
Last Posted Date
2019-02-12
Lead Sponsor
Ain Shams University
Target Recruit Count
188
Registration Number
NCT02776540
Locations
🇪🇬

Ain Shams University Hospitals, Cairo, Egypt

Cilostazol Following Peripheral Endovascular Procedures

Phase 3
Conditions
Peripheral Arterial Disease
Interventions
First Posted Date
2016-05-12
Last Posted Date
2021-01-12
Lead Sponsor
Attikon Hospital
Target Recruit Count
200
Registration Number
NCT02770274
Locations
🇬🇷

Patras Universityu Hospital, Patras, Achaia, Greece

🇬🇷

Attikon university General Hospital, Athens, Attiki, Greece

Effect of Aspirin on Gut Microbiome

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2016-05-04
Last Posted Date
2020-06-26
Lead Sponsor
University of Minnesota
Target Recruit Count
50
Registration Number
NCT02761486
Locations
🇺🇸

Epidemiology Clinical Research Center, Minneapolis, Minnesota, United States

Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer

Phase 4
Conditions
Prostate Cancer
Interventions
First Posted Date
2016-05-02
Last Posted Date
2016-05-02
Lead Sponsor
West China Hospital
Target Recruit Count
100
Registration Number
NCT02757365
Locations
🇨🇳

West Hospital of China, Chengdu, Sichuan, China

Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Not Applicable
Terminated
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2016-04-22
Last Posted Date
2019-02-15
Lead Sponsor
Fudan University
Target Recruit Count
52
Registration Number
NCT02748304
Locations
🇨🇳

Huashan hospital, Shanghai, China

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

Phase 4
Completed
Conditions
Coronary Artery Disease
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2016-04-22
Last Posted Date
2019-03-21
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
40
Registration Number
NCT02748330
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath